Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 9:11:627076.
doi: 10.3389/fendo.2020.627076. eCollection 2020.

Role of Sphingosine Kinase in Type 2 Diabetes Mellitus

Affiliations
Review

Role of Sphingosine Kinase in Type 2 Diabetes Mellitus

Yanfei Qi et al. Front Endocrinol (Lausanne). .

Abstract

Sphingolipids are a class of essential lipids, functioning as both cell membrane constituents and signaling messengers. In the sphingolipid metabolic network, ceramides serve as the central hub that is hydrolyzed to sphingosine, followed by phosphorylation to sphingosine 1-phosphate (S1P) by sphingosine kinase (SphK). SphK is regarded as a "switch" of the sphingolipid rheostat, as it catalyzes the conversion of ceramide/sphingosine to S1P, which often exhibit opposing biological roles in the cell. Besides, SphK is an important signaling enzyme that has been implicated in the regulation of a wide variety of biological functions. In recent years, an increasing body of evidence has suggested a critical role of SphK in type 2 diabetes mellitus (T2D), although a certain level of controversy remains. Herein, we review recent findings related to SphK in the field of T2D research with a focus on peripheral insulin resistance and pancreatic β-cell failure. It is expected that a comprehensive understanding of the role of SphK and the associated sphingolipids in T2D will help to identify druggable targets for future anti-diabetes therapy.

Keywords: ceramide; insulin resistance; sphingolipid; sphingosine 1-phosphate; β-cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Sphingolipid metabolic network. SPT, serine palmitoyltransferase; KDSR, 3-keto-dihydrosphingosine reductase; CerS, ceramide synthase; DEGS, dihydroceramide desaturase; CDase, ceramidase; SphK, sphingosine kinase; SPGL1, sphingosine 1-phosphate lyase.
Figure 2
Figure 2
Roles of SphK1 and SphK2 in T2D. Most of the literature supports an anti-diabetic role (denoted by green arrows) of SphK1 in skeletal muscle, adipose tissue and pancreas as well as SphK2 in the liver. In contrast, SphK2 is primarily a pro-diabetic factor (denoted by the red arrow) for its proapoptotic effects in pancreatic β-cells. The roles of SphK1 in the liver and SphK2 in skeletal muscle and adipose tissue are controversial (denoted by grey lines). Created in BioRender.com.

Similar articles

Cited by

References

    1. International Diabetes Federation IDF Diabetes Atlas 2019. (2019). - PubMed
    1. Albrink MJ. Diet, Diabetes, and Serum Lipids. Diabetes (1964) 13:425–9. 10.2337/diab.13.4.425 - DOI - PubMed
    1. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 510:84–91. 10.1038/nature13478 - DOI - PMC - PubMed
    1. Eid S, Sas KM, Abcouwer SF, Feldman EL, Gardner TW, Pennathur S, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia (2019) 62:1539–49. 10.1007/s00125-019-4959-1 - DOI - PMC - PubMed
    1. Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol (2019) 10:877. 10.3389/fphar.2019.00877 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances